Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DBV Technologies S.A.DBVT · Entity 5096 | Chief Medical Officer | July 29, 2026 | July 31, 2026 |
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Chief Medical Officer | January 15, 2019 | January 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DBV Technologies S.A.
Report date July 29, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 144,531 |
Reported balance
After 2026-07-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-29 · Sale · Disposed 464 · Balance 144,531 F1: The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares. F2: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1380 to EURO 1.00 as of July 29, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares.
F2: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
F3: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1380 to EURO 1.00 as of July 29, 2026.
Tempest Therapeutics, Inc.
Report date January 15, 2019 · Filed January 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2029-01-14 | Direct | 64,000 |
Reported balance
After 2019-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-15 · Grant · Acquired 64,000 · Balance 64,000 F1: Twenty-five percent (25%) of the shares subject to this option shall vest on January 15, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the shares subject to this option shall vest on January 15, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 31, 2026 20:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 464 | $2.70 | $1,252.80 |
DisclosureSEC source: 0001760395-26-000008 · form4-07312026_040701.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,531 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares. F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1380 to EURO 1.00 as of July 29, 2026. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:30 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 534 | $4.86 | $2,595.24 |
DisclosureSEC source: 0001760395-26-000002 · form4-02022026_040211.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,995 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares. F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · shares: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1974 to EURO 1.00 as of January 29, 2026. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 253,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001760395-25-000003 · form4-11252025_041101.xml · derivative · entry 4 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,000 Underlying: Ordinary Shares · 253,000 shares Expires 2035-11-21 F4 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025. F6 · derivative.exercise_date: The option shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantOrdinary Shares | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001760395-25-000003 · form4-11252025_041101.xml · nonDerivative · entry 3 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,529 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares. F5 · kind: Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 21, 2026, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 1,624 | $2.77 | $4,498.48 |
DisclosureSEC source: 0001760395-25-000003 · form4-11252025_041101.xml · nonDerivative · entry 2 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,529 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares. F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15154 to EURO 1.00 as of November 21, 2025. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 21:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 6,496 | $2.88 | $18,708.48 |
DisclosureSEC source: 0001760395-25-000003 · form4-11252025_041101.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,153 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares. F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.15268 to EURO 1.00 as of November 20, 2025. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 464 | $2.22 | $1,030.08 |
DisclosureSEC source: 0001415889-25-020722 · form4-07312025_040708.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,649 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares. F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: This sales price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1549 to EURO 1.00 as of July 29, 2025. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:10 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 397 | $1.84 | $730.48 |
DisclosureSEC source: 0001415889-25-014602 · form4-05272025_040501.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,113 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share. F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: This sales price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1303 to EURO 1.00 as of May 22, 2025. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 21:59 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 600 | $0.85 | $510.00 |
DisclosureSEC source: 0001415889-25-002509 · form4-01312025_090106.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,510 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share. F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: This sales price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0419 to EURO 1.00 as of January 30, 2025. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 565 | $0.57 | $322.05 |
DisclosureSEC source: 0001415889-24-027850 · form4-11272024_041114.xml · nonDerivative · entry 2 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,110 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share. F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: This sales price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.048 to EURO 1.00 as of November 25, 2024. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 21:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 342 | $0.53 | $181.26 |
DisclosureSEC source: 0001415889-24-027850 · form4-11272024_041114.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,675 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share. F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: This sales price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0469 to EURO 1.00 as of November 22, 2024. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 22:13 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 215,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-24-027648 · form4-11252024_101142.xml · derivative · entry 3 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 Underlying: Ordinary Shares · 215,000 shares Expires 2034-11-21 F4 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0546 to EURO 1.00 as of November 21, 2024. F5 · derivative.exercise_date: The option shall vest in four equal annual installments commencing on November 21, 2025, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 22:13 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 2,350 | $0.54 | $1,269.00 |
DisclosureSEC source: 0001415889-24-027648 · form4-11252024_101142.xml · nonDerivative · entry 2 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,017 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share. F3 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0546 to EURO 1.00 as of November 21, 2024. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 22:13 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027648 · form4-11252024_101142.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,367 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share. F2 · kind: Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 21, 2025, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 21:32 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 1,785 | $0.98 | $1,749.30 |
DisclosureSEC source: 0001415889-24-020466 · form4-07312024_090711.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,367 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one ordinary share. F2 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0823 to EURO 1.00 as of July 29, 2024. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 660 | $1.36 | $897.60 |
DisclosureSEC source: 0001415889-24-014759 · form4-05292024_040504.xml · nonDerivative · entry 2 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,152 F2 · price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0820 to EURO 1.00 as of May 24, 2024. Read SEC document |
| May 22, 2024 Filed May 29, 2024 20:15 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 382 | $1.38 | $527.16 |
DisclosureSEC source: 0001415889-24-014759 · form4-05292024_040504.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,812 F1 · price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0819 to EURO 1.00 as of May 22, 2024. Read SEC document |
| November 22, 2023 Filed Dec 19, 2023 21:44 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 2,245 | $1.74 | $3,906.30 |
DisclosureSEC source: 0001209191-23-059182 · doc4.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,194 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0941 to EURO 1.00 as of November 22, 2023. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 12:03 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 215,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-23-056408 · doc4.xml · derivative · entry 2 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,000 Underlying: Ordinary Shares · 215,000 shares Expires 2033-11-20 F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0928 to EURO 1.00 as of November 20, 2023. F3 · derivative.exercise_date: The option shall vest in four equal annual installments commencing on November 20, 2024, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 12:03 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056408 · doc4.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,439 F1 · kind: Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. The RSUs shall vest in four equal annual installments commencing on November 20, 2024, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 24, 2023 Filed Aug 14, 2023 20:32 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 469 | $3.54 | $1,660.26 |
DisclosureSEC source: 0001209191-23-045641 · doc4.xml · nonDerivative · entry 4 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,439 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share. F4 · kind: Shares sold to satisfy withholding tax obligations upon the the vesting of RSUs. F6 · price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0746 to EURO 1.00 as of May 24, 2023. Read SEC document |
| November 24, 2022 Filed Aug 14, 2023 20:32 UTC | DBV Technologies S.A. DBVT · Entity 5096 | SaleOrdinary Shares | 1,792 | $2.88 | $5,160.96 |
DisclosureSEC source: 0001209191-23-045641 · doc4.xml · nonDerivative · entry 3 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,908 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share. F4 · kind: Shares sold to satisfy withholding tax obligations upon the the vesting of RSUs. F5 · price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0409 to EURO 1.00 as of November 24, 2022. Read SEC document |
| November 21, 2022 Filed Aug 14, 2023 20:32 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001209191-23-045641 · doc4.xml · derivative · entry 6 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Ordinary Shares · 115,000 shares Expires 2032-11-21 F9 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0242 to EURO 1.00 as of November 21, 2022. F10 · derivative.exercise_date: 25% of the shares subject to the option vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| November 21, 2022 Filed Aug 14, 2023 20:32 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045641 · doc4.xml · nonDerivative · entry 2 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,700 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share. F3 · shares: Represents the Issuer's ordinary shares underlying a restricted stock unit RSU award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 29, 2022 Filed Aug 14, 2023 20:32 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001209191-23-045641 · doc4.xml · derivative · entry 5 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2032-07-29 F7 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0226 to EURO 1.00 as of July 29, 2022. F8 · derivative.exercise_date: 25% of the shares subject to the option vest on July 29, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 29, 2022 Filed Aug 14, 2023 20:32 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantOrdinary Shares | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045641 · doc4.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,200 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share. F2 · shares: Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on July 29, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:13 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantEmployee Stock Option (right to buy) · Derivative | 95,400 | $0.00 Strike: $6.62 | $0.00 |
DisclosureSEC source: 0001209191-21-066788 · doc4.xml · derivative · entry 2 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,400 Underlying: Ordinary Shares · 95,400 shares Expires 2031-11-22 F3 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1278 to EURO 1.00 as of November 22, 2021. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date. F1 · derivative.underlying: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:13 UTC | DBV Technologies S.A. DBVT · Entity 5096 | GrantOrdinary Shares | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066788 · doc4.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,200 F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share. F2 · shares: Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:49 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 64,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-19-004242 · doc4.xml · derivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on January 15, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 00:48 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 40,919 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-062125 · doc4.xml · derivative · entry 4 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,919 Underlying: Common Stock · 40,919 shares Expires 2028-08-23 F7 · price: Received in connection with the Merger in exchange for a stock option to acquire 550,000 shares of Millendo common stock for $1.22 per share. F6 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 00:48 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 37,485 | Not disclosed Strike: $4.44 | Not disclosed |
DisclosureSEC source: 0001209191-18-062125 · doc4.xml · derivative · entry 3 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,485 Underlying: Common Stock · 37,485 shares Expires 2026-01-27 F5 · price: Received in connection with the Merger in exchange for a stock option to acquire 503,847 shares of Millendo common stock for $0.33 per share. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on January 28, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 00:48 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 19,258 | Not disclosed Strike: $2.69 | Not disclosed |
DisclosureSEC source: 0001209191-18-062125 · doc4.xml · derivative · entry 2 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,258 Underlying: Common Stock · 19,258 shares Expires 2024-12-04 F3 · price: Received in connection with the Merger in exchange for a stock option to acquire 258,845 shares of Millendo common stock for $0.20 per share. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 00:48 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantCommon Stock | 7,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-062125 · doc4.xml · nonDerivative · entry 1 Mohideen Pharis · CIK 0001760395 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,440 F1 · price: Received in exchange for 100,000 shares of Millendo Therapeutics, Inc. ("Millendo") common stock in connection with merger of Millendo Therapeutics, Inc. into the Issuer (the "Merger"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.